Everyone complained when they spent up on prelaunch at CES in...

Everyone complained when they spent up on prelaunch at CES in anticipation of FDA approval, which was delayed.

I doubt they are going to make the same mistake this time, given the discontent from shareholders over frivolous spending.


I would want them to get everything right this time, the market has made it clear that there will be no mercy for them if they dont reach profitability off this current round of funding.

Imo there's no reason to rush just to placate bipolar investors.

Keep the powder dry, let those who want to soak enjoy the impatience of others.

I liked the reference to MSB the other day. Coiled spring waiting to snap. It is inevitable.